Specifically, patients taking SGLT-2 inhibitors were associated with a lower risk of hepatorenal syndrome (HR, 0.47 [95% CI, 0.40-0.56]; E-value, 3.89), variceal bleeding (HR, 0.79 [95% CI, 0.73-0.84]; E-value, 1.94), spontaneous bacterial peritonitis (HR, 0.55 [95% CI, 0.46-0.65]; E-value, 3.20), paracentesis (HR, 0.54 [95% CI, 0.50-0.60]; E-value, 2.15), hypoglycemia (HR, 0.75 [95% CI, 0.62-0.91]; E-value, 2.12), and all-cause hospitalizations (HR, 0.67 [95% CI, 0.63-0.71]; E-value, 2.90). The gene discussed is SLC5A2; the disease is liver disorder.